Research Interests

The Department of Clinical Chemistry is involved in both basic and applied science as well as clinical diagnostics. The broad analytical expertise in the Department contributes to the scientific output of the medical faculty especially in the fields of therapeutic drug monitoring,  mechanisms of disease, and proteomics. A major focus is therapeutic drug monitoring and the exploration of genetic and environmental factors that can alter individual drug dosage and action in order to achieve personalized pharmacotherapy. In this context, the Department of Clinical Chemistry has made internationally recognized, basic science and clinical contributions, especially in the pharmacokinetics, pharmacodynamics and pharmacogenetics of immunosuppressive drugs. Furthermore, our department has established a proteomics research and service platform, where studies are done on antigens associated with various pathogens, the pathogenic mechanisms of different diseases, drug targets, and posttranslational modifications. The department offers high quality analytical expertise in the field of mass spectrometry, which is a fundamental prerequisite for such research.

The use of real-time PCR equipment to genotype for known and to scan for unknown mutations in pharmacogenetically relevant genes is another important research activity. We are also studying biomarkers for the prediction of therapeutic success of immunomodulatory therapy in multiple sclerosis and the use of pharmacogenetics to tailor therapy early in the disease course to give best treatment to potential refractory cases. A prospective genome-wide association study is underway to identify new biomarkers for the treatment of multiple sclerosis.

Another clinically relevant area of research centers  on studies aimed at evaluating the diagnostic and prognostic value of innovative cardiac biomarkers (e.g. natriuretic peptide and cardiac troponins) for the diagnosis and treatment of different cardiac diseases (e.g. acute coronary syndrome, cardiac insufficiency, pulmonary embolism).